The data indicate CLYM116 showed a favourable safety profile, with no serious adverse events or dose-limiting toxicities.

Climb Bio, Inc. (NASDAQ:CLYM) shares rose 17% on Thursday after the clinical-stage biotechnology company released Phase 1 ...

Single 320 mg dose of CLYM116 drove near-complete APRIL suppression and 60-75% IgA/Gd-IgA1 suppression through 12 weeks CLYM116 ...

Climb Bio (CLYM) stock jumps on data from a Phase 1 trial for CLYM116, the company's anti-APRIL monoclonal antibody for IgA ...

ROCKVILLE, Md., July 20, 2026 (GLOBE NEWSWIRE)-- Today, the American Kidney Fund (AKF) and the IgA Nephrology Foundation announce the creation of a new resource for IgA nephropathy patients and their ...

In this video from GlomCon Hawaii, Dana Rizk, MD, discusses highlights from a presentation concerning the design and ...

Climb Bio, Inc.(NasdaqGM:CLYM) added to Russell 2500 Growth Benchmark CI Jun. 29 Climb Bio, Inc.(NasdaqGM:CLYM) added to Russell 2000 Value Benchmark CI Jun. 29 Climb Bio, Inc.(NasdaqGM:CLYM) added to ...

Treatment with telitacicept significantly reduced proteinuria in patients with immunoglobulin A (IgA) nephropathy compared with placebo, according to data from a phase 3 study involving more than 300 ...

After an IgA nephropathy (IgAN) diagnosis, your care team has likely discussed different treatment options with you, including some newer targeted therapies such as targeted-release budesonide or ...

Learn why Oxford scores predict IgA nephropathy outcomes, and how supportive drugs plus low-salt lifestyle protect remaining nephrons. How does targeted-release budesonide different from systemic ...

IgA nephropathy (IgAN) is a kidney disease involving immunoglobulin A (IgA) antibody buildup in the kidneys. Research suggests gut dysbiosis — an imbalance in gut bacteria — may contribute to IgAN by ...